Renormalization of dimension-six operators relevant for the Higgs decays h→γγ,γZh\rightarrow \gamma\gamma,\gamma Z

The discovery of the Higgs boson has opened a new window to test the SM through the measurements of its couplings. Of particular interest is the measured Higgs coupling to photons which arises in the SM at the one-loop level, and can then be significantly affected by new physics. We calculate the one-loop renormalization of the dimension-six operators relevant for $h\rightarrow \gamma\gamma, \gamma Z$, which can be potentially important since it could, in principle, give log-enhanced contributions from operator mixing. We find however that there is no mixing from any current-current operator that could lead to this log-enhanced effect. We show how the right choice of operator basis can make this calculation simple. We then conclude that $h\rightarrow \gamma\gamma, \gamma Z$ can only be affected by RG mixing from operators whose Wilson coefficients are expected to be of one-loop size, among them fermion dipole-moment operators which we have also included.Comment: 21 pages. Improved version with h -> gamma Z results added and structure of anomalous-dimension matrix determined further. Conclusions unchange

Perazzo 3-folds and the weak Lefschetz property

We deal with Perazzo 3-folds in P4, i.e. hypersurfaces X = V(f) subset of P4 of degree d defined by a homogeneous polynomial f(x0, x1, x2, u, v) = p0(u, v)x0 +p1(u, v)x1 + p2(u, v)x2 + g(u, v), where p0, p1, p2 are algebraically dependent but linearly independent forms of degree d - 1 in u, v, and g is a form in u, v of degree d. Perazzo 3-folds have vanishing hessian and, hence, the associated graded Artinian Gorenstein algebra Af fails the strong Lefschetz Property. In this paper, we determine the maximum and minimum Hilbert function of Af and we prove that if Af has maximal Hilbert function it fails the weak Lefschetz Property while it satisfies the weak Lefschetz Property when it has minimum Hilbert function. In addition, we classify all Perazzo 3-folds in P4 such that Af has minimum Hilbert function.(c) 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons .org /licenses /by -nc -nd /4 .0/)

Nonlinear optics of fibre event horizons

The nonlinear interaction of light in an optical fibre can mimic the physics at an event horizon. This analogue arises when a weak probe wave is unable to pass through an intense soliton, despite propagating at a different velocity. To date, these dynamics have been described in the time domain in terms of a soliton-induced refractive index barrier that modifies the velocity of the probe. Here, we complete the physical description of fibre-optic event horizons by presenting a full frequency-domain description in terms of cascaded four-wave mixing between discrete single-frequency fields, and experimentally demonstrate signature frequency shifts using continuous wave lasers. Our description is confirmed by the remarkable agreement with experiments performed in the continuum limit, reached using ultrafast lasers. We anticipate that clarifying the description of fibre event horizons will significantly impact on the description of horizon dynamics and soliton interactions in photonics and other systems.Comment: 7 pages, 5 figure

A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases

BACKGROUND The cytokine interleukin-2 (IL-2) can stimulate both effector immune cells and regulatory T (Treg) cells. The ability of selectively engaging either of these effects has spurred interest in using IL-2 for immunotherapy of cancer and autoimmune diseases. Thus, numerous IL-2-based biologic agents with improved bias or delivery towards effector immune cells or Treg cells have been developed. This study systematically reviews clinical results of improved IL-2-based compounds. METHODS We searched the ClinicalTrials.gov database for registered trials using improved IL-2-based agents and different databases for available results of these studies. FINDINGS From 576 registered clinical trials we extracted 36 studies on different improved IL-2-based compounds. Adding another nine agents reported in recent literature reviews and based on our knowledge totalled in 45 compounds. A secondary search for registered clinical trials of each of these 45 compounds resulted in 141 clinical trials included in this review, with 41 trials reporting results. INTERPRETATION So far, none of the improved IL-2-based compounds has gained regulatory approval for the treatment of cancer or autoimmune diseases. NKTR-214 is the only compound completing phase 3 studies. The PIVOT IO-001 trial testing the combination of NKTR-214 plus Pembrolizumab compared to Pembrolizumab monotherapy in metastatic melanoma missed its primary endpoints. Also the PIVOT-09 study, combining NKTR-214 with Nivolumab compared to Sunitinib or Cabozantinib in advanced renal cell carcinoma, missed its primary endpoint. Trials in autoimmune diseases are currently in early stages, thus not allowing definite conclusions on efficacy. FUNDING This work was supported by public funding agencies

Adaptive Immunosuppression in Lung Transplant Recipients Applying Complementary Biomarkers: The Zurich Protocol

Achieving adequate immunosuppression for lung transplant recipients in the first year after lung transplantation is a key challenge. Prophylaxis of allograft rejection must be balanced with the adverse events associated with immunosuppressive drugs, for example infection, renal failure, and diabetes. A triple immunosuppressive combination is standard, including a steroid, a calcineurin inhibitor, and an antiproliferative compound beginning with the highest levels of immunosuppression and a subsequent tapering of the dose, usually guided by therapeutic drug monitoring and considering clinical results, bronchoscopy sampling results, and additional biomarkers such as serum viral replication or donor-specific antibodies. Balancing the net immunosuppression level required to prevent rejection without overly increasing the risk of infection and other complications during the tapering phase is not well standardized and requires repeated assessments for dose-adjustments. In our adaptive immunosuppression approach, we additionally consider results from the white blood cell counts, in particular lymphocytes and eosinophils, as biomarkers for monitoring the level of immunosuppression and additionally use them as therapeutic targets to fine-tune the immunosuppressive strategy over time. The concept and its rationale are outlined, and areas of future research mentioned